医疗保险试点覆盖CBD, 而联邦监管机构调查FDA批准. Medicare pilots covering CBD while federal regulators investigate FDA approval.

医疗保险正在推进一个试点计划, 以覆盖来自大麻的CBD产品, 每年提供高达500美元的补贴, 但联邦监管机构正调查医疗和医疗服务中心是否绕过FDA药物批准标准. Medicare is advancing a pilot program to cover hemp-derived CBD products, offering up to $500 annually, but federal regulators are investigating whether the Centers for Medicare & Medicaid Services bypassed FDA drug approval standards. 批评者认为该计划在不需要FDA批准的配方或标准化剂量的情况下推进, 这引起了对安全性和一致性的担忧. Critics argue the program moves forward without requiring FDA-approved formulations or standardized dosing, raising concerns about safety and consistency. 美国国会准备收紧THC的联邦限制, 在扩大医疗保险和未来法律限制之间造成政策冲突. This comes as Congress prepares to tighten federal limits on THC in hemp, creating a policy conflict between expanding Medicare access and future legal restrictions.